MannKind Corp

MNKD

Add to Watchlist

3.090USD

-0.130-4.04%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

MannKind Corp's Score

Industry at a Glance

Industry Ranking

68 / 382

Overall Ranking

181 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

MannKind Corp Highlights

StrengthsRisks

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 75.39% year-on-year.

Undervalued

The company’s latest PE is -39.57, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 207.84M shares, increasing 10.46% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 1.76M shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

7.219

Target Price

+124.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of MannKind Corp is 7.96, ranking 56 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 90.17M, representing a year-over-year increase of 15.08%, while its net profit experienced a year-over-year increase of 226.30%.

Score

Industry at a Glance

Previous score

7.96

Change

0



Financials

5.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.53

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.53

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of MannKind Corp is 4.66, ranking 372 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -39.57, which is -569.07% below the recent high of 185.61 and -197.88% above the recent low of -117.87.

Score

Industry at a Glance

Previous score

4.66

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of MannKind Corp is 8.25, ranking 143 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 11.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.44

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of MannKind Corp is 7.17, ranking 93 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.06 and the support level at 2.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.29

Change

-0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of MannKind Corp is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 67.28%, representing a quarter-over-quarter increase of 17.51%. The largest institutional shareholder is James Simons, holding a total of 1.87M shares, representing 0.60% of shares outstanding, with 11.42% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

23.34M

-1.04%

State Street Investment Management (US)

10.74M

-0.05%

UBS Financial Services, Inc.

5.19M

+146.67%

Rubric Capital Management LP

11.41M

--

Geode Capital Management, L.L.C.

7.39M

-3.05%

Nitorum Capital, L.P.

6.56M

-6.42%

Dimensional Fund Advisors, L.P.

4.02M

-0.92%

Avoro Capital Advisors LLC

4.47M

-23.61%

180 Wealth Advisors, L.L.C.

2.87M

+11.24%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of MannKind Corp is 6.28, ranking 26 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. MannKind Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

MannKind Corp

MNKD

6.90 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment